Zhipeng Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Zhipeng Xu has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Jianning Wang
Shandong Provincial Qianfoshan Hospital, Shandong University
4 shared publications - Dan Wei
Department of Endocrinology and Metabolism, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Institute of Nephrology Jinan, Shandong, China
3 shared publications Dan Wei
Shandong First Medical University & Shandong Academy of Medical Sciences, The First Affiliated Hospital of Shandong First Medical University, Jinan, 250014, China
2 shared publicationsWei Zhang
Department of Gerontology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China
2 shared publications- Bin Wang
Department of Breast and Thyroid Surgery, Tengzhou Central People’s Hospital, Zaozhuang, Shandong, China
1 shared publication Cong Chen
Department of Urology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Organ Transplantation and Nephrosis, Shandong Institute of Nephrology, Jinan, Shandong, 250014, PR China
1 shared publication
Latest Publications
- 8 April 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (9) , 13997-14009
Network toxicology and single-cell transcriptomics nominate candidate pyrethroid-associated targets and pathways in clear cell renal cell carcinoma
Pyrethroid insecticides are widely used in agricultural and domestic settings. Increasing evidence suggests that pyrethroid exposure may harm multiple organ systems and is associated with potential carcinogenicity. However, the mechanisms linking pyrethroids to clear cell renal cell carcinoma (ccRCC) remain unclear. Using an integrative framework combining network toxicology, single-cell sequencing-based analyses, and molecular docking, we investigated putative core targets and associated signaling pathways through which six prevalent pyrethroid active ingredients in household insecticides may be involved in ccRCC development. We retrieved 710 putative targets of pyrethroid insecticides from three in silico databases (SwissTargetPrediction, SEA, and TargetNet). In parallel, 2633 ccRCC-associated genes were collected from GeneCards and OMIM. Differential expression analysis of the GSE36895 dataset was then used for cross-validation, yielding 50 overlapping genes between pyrethroid-related targets and ccRCC. Functional enrichment suggested that these genes were primarily involved in pathways including chemokine signaling, IgSF cell adhesion molecule signaling, and the p53 signaling pathway. Utilizing three machine-learning algorithms, PNP and TYMS were prioritized as the most informative hub genes. Immune infiltration analyses further evaluated associations between these genes and immune cell populations, while single-cell transcriptomic analyses characterized their expression patterns and cellular distribution across ccRCC subtypes. Finally, molecular binding and in vitro experiments demonstrated that pyrethroid compounds enhance the expression of PNP and TYMS, thereby promoting the development of ccRCC. Overall, our research suggests that PNP and TYMS are candidate targets of pyrethroid insecticides involved in ccRCC, providing a mechanistic foundation for future targeted therapies.
- 8 April 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (9) , 13997-14009
Network toxicology and single-cell transcriptomics nominate candidate pyrethroid-associated targets and pathways in clear cell renal cell carcinoma
Pyrethroid insecticides are widely used in agricultural and domestic settings. Increasing evidence suggests that pyrethroid exposure may harm multiple organ systems and is associated with potential carcinogenicity. However, the mechanisms linking pyrethroids to clear cell renal cell carcinoma (ccRCC) remain unclear. Using an integrative framework combining network toxicology, single-cell sequencing-based analyses, and molecular docking, we investigated putative core targets and associated signaling pathways through which six prevalent pyrethroid active ingredients in household insecticides may be involved in ccRCC development. We retrieved 710 putative targets of pyrethroid insecticides from three in silico databases (SwissTargetPrediction, SEA, and TargetNet). In parallel, 2633 ccRCC-associated genes were collected from GeneCards and OMIM. Differential expression analysis of the GSE36895 dataset was then used for cross-validation, yielding 50 overlapping genes between pyrethroid-related targets and ccRCC. Functional enrichment suggested that these genes were primarily involved in pathways including chemokine signaling, IgSF cell adhesion molecule signaling, and the p53 signaling pathway. Utilizing three machine-learning algorithms, PNP and TYMS were prioritized as the most informative hub genes. Immune infiltration analyses further evaluated associations between these genes and immune cell populations, while single-cell transcriptomic analyses characterized their expression patterns and cellular distribution across ccRCC subtypes. Finally, molecular binding and in vitro experiments demonstrated that pyrethroid compounds enhance the expression of PNP and TYMS, thereby promoting the development of ccRCC. Overall, our research suggests that PNP and TYMS are candidate targets of pyrethroid insecticides involved in ccRCC, providing a mechanistic foundation for future targeted therapies.
- Open Access
- 23 January 2026
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 26 (1)
Calcitonin-negative medullary thyroid carcinoma combined with multifocal papillary thyroid carcinoma: a case report and literature review
Calcitonin-negative medullary thyroid cancer (CTNMTC) is a rare primary thyroid neuroendocrine carcinoma characterised by medullary thyroid carcinoma (MTC)
- 23 January 2026
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 26 (1)
Open AccessCalcitonin-negative medullary thyroid carcinoma combined with multifocal papillary thyroid carcinoma: a case report and literature review
Calcitonin-negative medullary thyroid cancer (CTNMTC) is a rare primary thyroid neuroendocrine carcinoma characterised by medullary thyroid carcinoma (MTC)
- Open Access
- 19 May 2023
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 743, 109642
ApoM suppresses kidney renal clear cell carcinoma growth and metastasis via the Hippo-YAP signaling pathway
- 19 May 2023
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 743, 109642
Open AccessApoM suppresses kidney renal clear cell carcinoma growth and metastasis via the Hippo-YAP signaling pathway
- Open Access
- 13 February 2023
- Published by Wiley in Journal of Oncology
- Vol. 2023, 1-14
SLC9A1 Binding mTOR Signaling Pathway-Derived Risk Score Predicting Survival and Immune in Clear Cell Renal Cell Carcinoma
Objective. Clear cell renal cell carcinoma (ccRCC) is one of the common renal cell carcinomas (RCC) with a high risk of recurrence. Considering that SLC9A1 is involved in various cellular physiological processes and probably mediates the course of mTOR signaling in tumors, this study constructed a risk model for SLC9A1 combined with mTOR signaling in ccRCC, aiming at better predicting the prognosis of patients. Methods. ccRCC expression matrices were downloaded from TCGA and ICGC databases to compare the expression of SLC9A1 in TCGA, and qRT-PCR was adopted to validate the SLC9A1 expression in different RCC cells and normal kidney cells. The CIBERSORT and ESTIMATE algorithms were used to assess samples for immunity. mTOR signaling-associated genes were downloaded from the KEGG website, and then the genes were adopted to screen genes associated with SLC9A1 expression and mTOR signaling pathway colleagues, based on which univariate COX regression and lasso regression Cox analyses were conducted to construct a ccRCC prognostic risk model. ROC curves and nomograms were used to assess the validity of the models. Results. ccRCC tumor samples showed lower SLC9A1 expression than normal samples, as also evidenced by qRT-PCR. The SLC9A1 expression was highly correlated with tumor immunity. Totally, 564 key genes associated with both SLC9A1 expression and mTOR signaling were screened out, and the risk model consisting of 11 gene signatures was constructed in ccRCC based on the 564 genes. Since patients at a high risk had poorer survival outcomes, the high-risk group presented poorer immunotherapy outcomes. Moreover, a higher clinical grade of patients suggested a higher risk score. The risk score can serve as one independent prognostic factor for the prognosis prediction of ccRCC patients. Conclusion. An extremely promising prognostic indicator for ccRCC based on SLCA9A1 and mTOR signaling has been constructed to provide reference for clinical treatment.
- 13 February 2023
- Published by Wiley in Journal of Oncology
- Vol. 2023, 1-14
Open AccessSLC9A1 Binding mTOR Signaling Pathway-Derived Risk Score Predicting Survival and Immune in Clear Cell Renal Cell Carcinoma
Objective. Clear cell renal cell carcinoma (ccRCC) is one of the common renal cell carcinomas (RCC) with a high risk of recurrence. Considering that SLC9A1 is involved in various cellular physiological processes and probably mediates the course of mTOR signaling in tumors, this study constructed a risk model for SLC9A1 combined with mTOR signaling in ccRCC, aiming at better predicting the prognosis of patients. Methods. ccRCC expression matrices were downloaded from TCGA and ICGC databases to compare the expression of SLC9A1 in TCGA, and qRT-PCR was adopted to validate the SLC9A1 expression in different RCC cells and normal kidney cells. The CIBERSORT and ESTIMATE algorithms were used to assess samples for immunity. mTOR signaling-associated genes were downloaded from the KEGG website, and then the genes were adopted to screen genes associated with SLC9A1 expression and mTOR signaling pathway colleagues, based on which univariate COX regression and lasso regression Cox analyses were conducted to construct a ccRCC prognostic risk model. ROC curves and nomograms were used to assess the validity of the models. Results. ccRCC tumor samples showed lower SLC9A1 expression than normal samples, as also evidenced by qRT-PCR. The SLC9A1 expression was highly correlated with tumor immunity. Totally, 564 key genes associated with both SLC9A1 expression and mTOR signaling were screened out, and the risk model consisting of 11 gene signatures was constructed in ccRCC based on the 564 genes. Since patients at a high risk had poorer survival outcomes, the high-risk group presented poorer immunotherapy outcomes. Moreover, a higher clinical grade of patients suggested a higher risk score. The risk score can serve as one independent prognostic factor for the prognosis prediction of ccRCC patients. Conclusion. An extremely promising prognostic indicator for ccRCC based on SLCA9A1 and mTOR signaling has been constructed to provide reference for clinical treatment.
- Open Access
- 1 January 2022
- Published by XMLink in Yonsei Medical Journal
- Vol. 63 (7) , 619-631
Canagliflozin Ameliorates Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism and Inhibiting Inflammation through Induction of Autophagy
Xu Z, et al. Yonsei Med J. 2022 Jul;63(7):619-631. https://doi.org/10.3349/ymj.2022.63.7.619
- 1 January 2022
- Published by XMLink in Yonsei Medical Journal
- Vol. 63 (7) , 619-631
Open AccessCanagliflozin Ameliorates Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism and Inhibiting Inflammation through Induction of Autophagy
Xu Z, et al. Yonsei Med J. 2022 Jul;63(7):619-631. https://doi.org/10.3349/ymj.2022.63.7.619
- 1 August 2021
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 99 (8) , 775-785
Theobromine ameliorates nonalcoholic fatty liver disease by regulating hepatic lipid metabolism via mTOR signaling pathway in vivo and in vitro
Theobromine, a methylxanthine present in cocoa, has been shown to possess many beneficial pharmacological properties such as anti-oxidative stress, anti-inflammatory property, and anti-microbial activity. In this study, we investigated the effects of theobromine on nonalcoholic fatty liver disease (NAFLD) and the possible underlying mechanisms in vivo and in vitro. The results showed that theobromine reduced body weight and fat mass and improved dyslipidemia. Theobromine mitigated liver injury and significantly reduced hepatic triglyceride level in mice with obesity. Histological examinations also showed hepatic steatosis was alleviated after theobromine treatment. Furthermore, theobromine reversed the elevated mRNA and protein expression of SREBP-1c, FASN, CD36, FABP4, and the suppressed expression of PPARα and CPT1a in the liver of mice with obesity, which were responsible for lipogenesis, fatty acid uptake, and fatty acid oxidation respectively. In vitro, theobromine also downregulated SREBP-1c, FASN, CD36, FABP4 and upregulated PPARα and CPT1a mRNA and protein levels in hepatocytes in a dose-dependent manner, while these changes were reversed by L-leucine, a mammalian target of rapamycin (mTOR) agonist. The present study demonstrated that theobromine improved NAFLD by inhibiting lipogenesis and fatty acid uptake and promoting fatty acid oxidation in the liver and hepatocytes, which might be associated with its suppression of mTOR signaling pathway. Novelty: Theobromine protects against high-fat diet – induced NAFLD. Theobromine inhibits lipogenesis and fatty acid uptake and promotes fatty acid oxidation in the liver and hepatocytes via inhibiting mTOR signaling pathway.
- 1 August 2021
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 99 (8) , 775-785
Theobromine ameliorates nonalcoholic fatty liver disease by regulating hepatic lipid metabolism via mTOR signaling pathway in vivo and in vitro
Theobromine, a methylxanthine present in cocoa, has been shown to possess many beneficial pharmacological properties such as anti-oxidative stress, anti-inflammatory property, and anti-microbial activity. In this study, we investigated the effects of theobromine on nonalcoholic fatty liver disease (NAFLD) and the possible underlying mechanisms in vivo and in vitro. The results showed that theobromine reduced body weight and fat mass and improved dyslipidemia. Theobromine mitigated liver injury and significantly reduced hepatic triglyceride level in mice with obesity. Histological examinations also showed hepatic steatosis was alleviated after theobromine treatment. Furthermore, theobromine reversed the elevated mRNA and protein expression of SREBP-1c, FASN, CD36, FABP4, and the suppressed expression of PPARα and CPT1a in the liver of mice with obesity, which were responsible for lipogenesis, fatty acid uptake, and fatty acid oxidation respectively. In vitro, theobromine also downregulated SREBP-1c, FASN, CD36, FABP4 and upregulated PPARα and CPT1a mRNA and protein levels in hepatocytes in a dose-dependent manner, while these changes were reversed by L-leucine, a mammalian target of rapamycin (mTOR) agonist. The present study demonstrated that theobromine improved NAFLD by inhibiting lipogenesis and fatty acid uptake and promoting fatty acid oxidation in the liver and hepatocytes, which might be associated with its suppression of mTOR signaling pathway. Novelty: Theobromine protects against high-fat diet – induced NAFLD. Theobromine inhibits lipogenesis and fatty acid uptake and promotes fatty acid oxidation in the liver and hepatocytes via inhibiting mTOR signaling pathway.
- 1 April 2020
- Published by Elsevier in Life Sciences
- Vol. 247, 117414
Canagliflozin ameliorates obesity by improving mitochondrial function and fatty acid oxidation via PPARα in vivo and in vitro
- 1 April 2020
- Published by Elsevier in Life Sciences
- Vol. 247, 117414
Canagliflozin ameliorates obesity by improving mitochondrial function and fatty acid oxidation via PPARα in vivo and in vitro